Xintela AB (publ) (STO:XINT)
0.1680
+0.0030 (1.82%)
Sep 2, 2026, 3:48 PM CET
Xintela AB Revenue
Xintela AB had revenue of 1.32M SEK in the quarter ending June 30, 2026, with 51.03% growth. This brings the company's revenue in the last twelve months to 3.03M, down -38.46% year-over-year. In the year 2025, Xintela AB had annual revenue of 2.28M, down -45.86%.
Revenue (ttm)
3.03M
Revenue Growth
-38.46%
P/S Ratio
47.77
Revenue / Employee
275.36K
Employees
11
Market Cap
144.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.28M | -1.93M | -45.86% |
| Dec 31, 2024 | 4.22M | 2.41M | 133.26% |
| Dec 31, 2023 | 1.81M | -1.57M | -46.46% |
| Dec 31, 2022 | 3.38M | 1.04M | 44.79% |
| Dec 31, 2021 | 2.33M | -12.62M | -84.40% |
| Dec 31, 2020 | 14.95M | 9.27M | 163.20% |
| Dec 31, 2019 | 5.68M | 4.05M | 248.83% |
| Dec 31, 2018 | 1.63M | 1.63M | 81,300.00% |
| Dec 31, 2017 | 2.00K | -1.00K | -33.33% |
| Dec 31, 2016 | 3.00K | -754.00K | -99.60% |
| Dec 31, 2015 | 757.00K | 384.00K | 102.95% |
| Dec 31, 2014 | 373.00K | -425.31M | -99.91% |
| Dec 31, 2013 | 425.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xbrane Biopharma AB | 83.30M |
| Nanologica AB | 31.83M |
| Biovica International AB | 13.49M |
| NextCell Pharma AB | 10.78M |
| Abera Bioscience AB | 9.10M |
| Elicera Therapeutics AB | 7.79M |
| Simris Group AB (PUBL) | 1.39M |
| Diamyd Medical AB | 432.00K |
Xintela AB News
- 5 days ago - Xintela AB Quarterly report: Q2 2026 - Filings
- 3 months ago - Xintela AB Quarterly report: Q1 2026 - Filings
- 6 months ago - Xintela AB Quarterly report: Q4 2025 - Filings
- 6 months ago - Xintela AB Annual report: Q4 2025 - Filings
- 10 months ago - Xintela AB Quarterly report: Q3 2025 - Filings
- 11 months ago - Xintela AB Transcript: Investing in Life Science 2025 - Transcripts